AstraZeneca PLC (AZN)

NYSE: AZN · Real-Time Price · USD
169.64
-1.70 (-0.99%)
At close: Jul 31, 2026, 4:00 PM EDT
162.46
-7.18 (-4.23%)
Pre-market: Aug 3, 2026, 8:00 AM EDT
Market Cap263.74B +11.1%
Revenue (ttm)61.37B +8.6%
Net Income10.45B +25.9%
EPS6.68 +25.8%
Shares Out 1.55B
PE Ratio25.25
Forward PE15.68
Dividend$3.23 (1.90%)
Ex-Dividend DateAug 7, 2026
Volume1,670,009
Open170.53
Previous Close171.34
Day's Range168.44 - 170.74
52-Week Range141.77 - 212.71
Beta0.23
AnalystsBuy
Price Target213.69 (+25.97%)
Earnings DateJul 27, 2026

About AZN

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]

Sector Healthcare
IPO Date May 12, 1993
Employees 95,100
Stock Exchange NYSE
Ticker Symbol AZN
Full Company Profile

Financial Performance

In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.

Financial Statements

Analyst Summary

According to 10 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is $213.69, which is an increase of 25.97% from the latest price.

Price Target
$213.69
(25.97% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Citi views report of AstraZeneca, Bristol Myers talks as surprising

Citi analyst Graham Parry is surprised by the Financial Times report of a potential merger between AstraZeneca (AZN) and Bristol Myers (BMY). The firm believes Astra’s pipeline is “best-in-sector” and...

Other symbols: BMY
1 hour ago - TheFly

AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.

AstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the...

1 hour ago - Market Watch

Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca

The merger would be one of the biggest pharma deals ever. AstraZeneca's market capitalization stood at $264 billion as of Friday's close, while Bristol Myers Squibb had a total valuation of $133 billi...

2 hours ago - Barrons

AstraZeneca (AZN) Stock Plummets Amid Merger Talks with Bristol-Myers Squibb

AstraZeneca (AZN) Stock Plummets Amid Merger Talks with Bristol-Myers Squibb

2 hours ago - GuruFocus

AstraZeneca Weighs a Deal Its CEO Said It Didn't Need

AstraZeneca Weighs a Deal Its CEO Said It Didn't Need

2 hours ago - GuruFocus

AstraZeneca and Bristol Myers Squibb Explore $400 Billion Merger

AstraZeneca and Bristol Myers Squibb Explore $400 Billion Merger

2 hours ago - GuruFocus

AstraZeneca drops 6% to $159.98 after report of Bristol Myers merger talks

05:01 EDT AstraZeneca (AZN) drops 6% to $159.98 after report of Bristol Myers (BMY) merger talks

Other symbols: BMY
2 hours ago - TheFly

Bristol Myers jumps 8% to $70.47 after report of AstraZeneca merger talks

05:02 EDT Bristol Myers (BMY) jumps 8% to $70.47 after report of AstraZeneca (AZN) merger talks

Other symbols: BMY
2 hours ago - TheFly

Why did AstraZeneca shares fall 6% after Bristol Myers Squibb merger reports?

AstraZeneca shares fell more than 6% in early trading on Monday after reports emerged that the British pharmaceutical giant had held preliminary discussions with US-based Bristol Myers Squibb over a p...

3 hours ago - Invezz

AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks

If maintained until close, the decline would be the stock's biggest one-day percentage fall since the day of the 2024 U.S. presidential election.

3 hours ago - WSJ

AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb

AstraZeneca is reportedly in talks with U.S. peer Bristol Myers Squibb over a megadeal. If completed, a combined company could be valued at roughly roughly $400 billion.

4 hours ago - CNBC

AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger

A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.

4 hours ago - This is Money

AstraZeneca shares tumble 7% after reported Bristol Myers talks

AstraZeneca shares tumbled 7% in early ​trading on Monday following reports of ‌talks between the European pharmaceutical giant and U.S.-based Bristol Myers Squibb , baffling investors and analysts.

4 hours ago - Reuters

AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger

Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updates Britain’s biggest drugmaker AstraZeneca is in discussions to...

4 hours ago - The Guardian

AstraZeneca, Bristol Myers Squibb Hold Early Merger Talks for Potential $400B Deal

British drug giant AstraZeneca ($AZN) and U.S.-based Bristol Myers Squibb ($BMY) have held talks about a potential merger that could create one of the world’s largest pharmaceutical companies. Accordi...

Other symbols: BMY
5 hours ago - TipRanks

AstraZeneca And Bristol Myers Reportedly In Talks On $400 Bln Deal

(RTTNews) - AstraZeneca Plc (AZN) and Bristol Myers Squibb (BMY) are in talks over a $400 billion deal to combine the companies, Financial Times reported.

6 hours ago - Nasdaq

AstraZeneca and Bristol-Myers Squibb Explore Potential Merger

AstraZeneca and Bristol-Myers Squibb Explore Potential Merger

10 hours ago - GuruFocus

AZN Looks 5.5% Undervalued on GF Value™ Amid $400B Merger Talks

AZN Looks 5.5% Undervalued on GF Value™ Amid $400B Merger Talks

10 hours ago - GuruFocus

AstraZeneca Considers Merger with Bristol-Myers Squibb, Valued at $400 Billion

AstraZeneca Considers Merger with Bristol-Myers Squibb, Valued at $400 Billion

11 hours ago - GuruFocus

AstraZeneca in discussions to combine with Bristol Myers for $400B, FT says

AstraZeneca (AZN) is in discussions to combine with Bristol Myers Squibb (BMY) in a deal valued at nearly $400B, Oliver Barnes, James Fontanella-Khan, Aaron Kirchfeld, and Arash Massoudi of The…

Other symbols: BMY
11 hours ago - TheFly

AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report

The deal could create one of the world's biggest pharmaceutical groups with a combined value of nearly $400 billion.

14 hours ago - New York Post

AZN Looks 5.5% Undervalued on GF Value™ Amid Strong Dividend Profile

AZN Looks 5.5% Undervalued on GF Value™ Amid Strong Dividend Profile

15 hours ago - GuruFocus

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times. The megadeal would be one of the large...

16 hours ago - CNBC

AstraZeneca holds talks with Bristol Myers Squibb on potential megadeal, FT reports

UK drugmaker AstraZeneca has ​been exploring a deal to ‌combine with U.S. rival Bristol Myers Squibb , the Financial Times reported on Sunday, ​citing people familiar with the ​matter.

16 hours ago - Reuters